Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=184 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2028 ➔ Jul 2029 | Trial primary completion date: Jul 2028 ➔ Jul 2029
Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
|